Last reviewed · How we verify
Mepem
Mepem, marketed by Yung Shin Pharm. Ind. Co., Ltd., is an established drug in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its approved mechanism and primary indication. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Mepem |
|---|---|
| Sponsor | Yung Shin Pharm. Ind. Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Pharmacokinetics of Meropenem in Severe Septic Patients (PHASE4)
- A Study the Population Pharmacokinetics of Children of Infectious Disease in Central Nervous System
- Bioequivalence of Two Formulations of Meropenem Intravenous Injection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mepem CI brief — competitive landscape report
- Mepem updates RSS · CI watch RSS
- Yung Shin Pharm. Ind. Co., Ltd. portfolio CI